Jones Financial Companies
PCSA icon

Jones Financial Companies’s Processa Pharmaceuticals PCSA Stock Holding History

Jones Financial Companies’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17 Hold
7
– – ﹤0.01% 4692
2025
Q4 		$20 Sell
7
-1
-13% -$7 ﹤0.01% 4368
2025
Q3 		$40 Buy
+8
New +$42 ﹤0.01% 4186

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Jones Financial Companies's PCSA Position: Q1 2026 in Review

Jones Financial Companies held its Processa Pharmaceuticals (PCSA) position steady in Q1 2026 at 7 shares worth $17. The position accounts for ﹤0.01% of the portfolio, ranked #4692.

Jones Financial Companies first reported a position in PCSA in Q3 2025 and has held it in 3 quarters since. The position peaked at $40 in Q3 2025. 10 funds tracked by Wall St. Rank hold PCSA as of Q1 2026.

  • Jones Financial Companies held 7 shares of Processa Pharmaceuticals worth $17 as of Q1 2026.
  • Jones Financial Companies left its Processa Pharmaceuticals share count unchanged in Q1 2026.
  • Processa Pharmaceuticals made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4692 holding.
  • Jones Financial Companies first reported a position in Processa Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Jones Financial Companies's Processa Pharmaceuticals position peaked at $40 in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.